Cargando…
Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A compr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509371/ https://www.ncbi.nlm.nih.gov/pubmed/28704521 http://dx.doi.org/10.1371/journal.pone.0181447 |
_version_ | 1783250013765238784 |
---|---|
author | Li, Jia Wang, Ningning Tesfaluul, Nahom Gao, Xiaojuan Liu, Shuai Yue, Baohong |
author_facet | Li, Jia Wang, Ningning Tesfaluul, Nahom Gao, Xiaojuan Liu, Shuai Yue, Baohong |
author_sort | Li, Jia |
collection | PubMed |
description | PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A comprehensive literary search for relevant studies was performed on PubMed, Embase, Medline, CNKI (Chinese) and Web of Science databases (January 1, 1950 to December 20, 2016). The associations between CPCs and survival rate and clinicopathological parameters, including International staging system (ISS) and Durie-Salm staging system (DS) stage, were evaluated. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analysis, sensitivity analysis, and publication bias were conducted. RESULTS: 11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression (HR = 1.78, 95% CI = 1.57–2.03) and reduced overall survival (OS) (HR = 1.82, 95% CI = 1.59–2.08). Subgroup analyses demonstrated that CPCs positive patients also had poor disease progression and OS in detection methods and sampling time subsets. Moreover, the presence of CPCs was strikingly associated with increased ISS stage (OR = 2.78% CI = 1.69–4.56), but not with DS stage(OR = 1.60; 95% CI = 0.74–3.47). CONCLUSIONS: CPCs status is associated with poorer survival outcome in multiple myeloma. Additionally, increased ISS stage could be significant risk factors for the presence of CPCs. |
format | Online Article Text |
id | pubmed-5509371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55093712017-08-07 Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis Li, Jia Wang, Ningning Tesfaluul, Nahom Gao, Xiaojuan Liu, Shuai Yue, Baohong PLoS One Research Article PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A comprehensive literary search for relevant studies was performed on PubMed, Embase, Medline, CNKI (Chinese) and Web of Science databases (January 1, 1950 to December 20, 2016). The associations between CPCs and survival rate and clinicopathological parameters, including International staging system (ISS) and Durie-Salm staging system (DS) stage, were evaluated. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analysis, sensitivity analysis, and publication bias were conducted. RESULTS: 11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression (HR = 1.78, 95% CI = 1.57–2.03) and reduced overall survival (OS) (HR = 1.82, 95% CI = 1.59–2.08). Subgroup analyses demonstrated that CPCs positive patients also had poor disease progression and OS in detection methods and sampling time subsets. Moreover, the presence of CPCs was strikingly associated with increased ISS stage (OR = 2.78% CI = 1.69–4.56), but not with DS stage(OR = 1.60; 95% CI = 0.74–3.47). CONCLUSIONS: CPCs status is associated with poorer survival outcome in multiple myeloma. Additionally, increased ISS stage could be significant risk factors for the presence of CPCs. Public Library of Science 2017-07-13 /pmc/articles/PMC5509371/ /pubmed/28704521 http://dx.doi.org/10.1371/journal.pone.0181447 Text en © 2017 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Li, Jia Wang, Ningning Tesfaluul, Nahom Gao, Xiaojuan Liu, Shuai Yue, Baohong Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title_full | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title_fullStr | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title_full_unstemmed | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title_short | Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis |
title_sort | prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509371/ https://www.ncbi.nlm.nih.gov/pubmed/28704521 http://dx.doi.org/10.1371/journal.pone.0181447 |
work_keys_str_mv | AT lijia prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis AT wangningning prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis AT tesfaluulnahom prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis AT gaoxiaojuan prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis AT liushuai prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis AT yuebaohong prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis |